Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

71 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
BH3 profiling identifies ruxolitinib as a promising partner for venetoclax to treat T-cell prolymphocytic leukemia.
Herbaux C, Kornauth C, Poulain S, Chong SJF, Collins MC, Valentin R, Hackett L, Tournilhac O, Lemonnier F, Dupuis J, Daniel A, Tomowiak C, Laribi K, Renaud L, Roos-Weil D, Rossi C, Van Den Neste E, Leyronnas C, Merabet F, Malfuson JV, Tiab M, Ysebaert L, Ng S, Morschhauser F, Staber PB, Davids MS. Herbaux C, et al. Among authors: malfuson jv. Blood. 2021 Jun 24;137(25):3495-3506. doi: 10.1182/blood.2020007303. Blood. 2021. PMID: 33598678 Free article. Clinical Trial.
VTD is superior to VCD prior to intensive therapy in multiple myeloma: results of the prospective IFM2013-04 trial.
Moreau P, Hulin C, Macro M, Caillot D, Chaleteix C, Roussel M, Garderet L, Royer B, Brechignac S, Tiab M, Puyade M, Escoffre M, Stoppa AM, Facon T, Pegourie B, Chaoui D, Jaccard A, Slama B, Marit G, Laribi K, Godmer P, Luycx O, Eisenmann JC, Allangba O, Dib M, Araujo C, Fontan J, Belhadj K, Wetterwald M, Dorvaux V, Fermand JP, Rodon P, Kolb B, Glaisner S, Malfuson JV, Lenain P, Biron L, Planche L, Caillon H, Avet-Loiseau H, Dejoie T, Attal M. Moreau P, et al. Among authors: malfuson jv. Blood. 2016 May 26;127(21):2569-74. doi: 10.1182/blood-2016-01-693580. Epub 2016 Mar 21. Blood. 2016. PMID: 27002117 Free article. Clinical Trial.
Efficacy of chemotherapy or chemo-anti-PD-1 combination after failed anti-PD-1 therapy for relapsed and refractory Hodgkin lymphoma: A series from Lysa centers.
Rossi C, Gilhodes J, Maerevoet M, Herbaux C, Morschhauser F, Brice P, Garciaz S, Borel C, Ysebaert L, Obéric L, Lazarovici J, Deau B, Dupuis J, Chauchet A, Abraham J, Bijou F, Stamatoullas-Bastard A, Malfuson JV, Golfier C, Laurent C, Pericart S, Traverse-Glehen A, Kanoun S, Filleron T, Casasnovas RO, Ghesquières H. Rossi C, et al. Among authors: malfuson jv. Am J Hematol. 2018 Jun 8. doi: 10.1002/ajh.25154. Online ahead of print. Am J Hematol. 2018. PMID: 29884994 Free article.
Carfilzomib Weekly plus Melphalan and Prednisone in Newly Diagnosed Transplant-Ineligible Multiple Myeloma (IFM 2012-03): A Phase I Trial.
Leleu X, Fouquet G, Richez V, Guidez S, Duhamel A, Machuron F, Karlin L, Kolb B, Tiab M, Araujo C, Meuleman N, Malfuson JV, Bourquard P, Lenain P, Roussel M, Jaccard A, Pétillon MO, Belhadj-Merzoug K, Lepeu G, Chrétien ML, Fontan J, Rodon P, Schmitt A, Offner F, Voillat L, Cereja S, Kuhnowski F, Rigaudeau S, Decaux O, Humbrecht-Kraut C, Frayfer J, Fitoussi O, Roos-Weil D, Eisenmann JC, Dorvaux V, Voog EG, Attal M, Moreau P, Avet-Loiseau H, Hulin C, Facon T. Leleu X, et al. Among authors: malfuson jv. Clin Cancer Res. 2019 Jul 15;25(14):4224-4230. doi: 10.1158/1078-0432.CCR-18-3642. Epub 2019 May 3. Clin Cancer Res. 2019. PMID: 31053600 Clinical Trial.
Daratumumab and dexamethasone is safe and effective for triple refractory myeloma patients: final results of the IFM 2014-04 (Etoile du Nord) trial.
Boyle EM, Leleu X, Petillon MO, Karlin L, Doyen C, Demarquette H, Royer B, Macro M, Moreau P, Fostier K, Marie-Lorraine C, Zarnitsky C, Perrot A, Herbaux C, Poulain S, Manier S, Beauvais D, Walker BA, Wardell CP, Vincent L, Frenzel L, Caillon H, Susanna S, Dejoie T, Avet-Loiseau H, Mohty M, Facon T; IFM2014-04 investigators. Boyle EM, et al. Br J Haematol. 2019 Nov;187(3):319-327. doi: 10.1111/bjh.16059. Epub 2019 Jun 19. Br J Haematol. 2019. PMID: 31218679 Free article. Clinical Trial.
Mutational profile and benefit of gemtuzumab ozogamicin in acute myeloid leukemia.
Fournier E, Duployez N, Ducourneau B, Raffoux E, Turlure P, Caillot D, Thomas X, Marceau-Renaut A, Chantepie S, Malfuson JV, Lemasle E, Cheok M, Celli-Lebras K, Guerin E, Terré C, Lambert J, Pautas C, Dombret H, Castaigne S, Preudhomme C, Boissel N. Fournier E, et al. Among authors: malfuson jv. Blood. 2020 Feb 20;135(8):542-546. doi: 10.1182/blood.2019003471. Blood. 2020. PMID: 31880804 Free article. Clinical Trial.
Added prognostic value of secondary AML-like gene mutations in ELN intermediate-risk older AML: ALFA-1200 study results.
Gardin C, Pautas C, Fournier E, Itzykson R, Lemasle E, Bourhis JH, Adès L, Marolleau JP, Malfuson JV, Gastaud L, Raffoux E, Lambert J, Braun T, Thomas X, Chantepie S, Cluzeau T, de Botton S, Berthon C, Boissel N, Duployez N, Terré C, Peffault de Latour R, Michallet M, Celli-Lebras K, Preudhomme C, Dombret H. Gardin C, et al. Among authors: malfuson jv. Blood Adv. 2020 May 12;4(9):1942-1949. doi: 10.1182/bloodadvances.2019001349. Blood Adv. 2020. PMID: 32380535 Free PMC article.
A personalized approach to guide allogeneic stem cell transplantation in younger adults with acute myeloid leukemia.
Fenwarth L, Thomas X, de Botton S, Duployez N, Bourhis JH, Lesieur A, Fortin G, Meslin PA, Yakoub-Agha I, Sujobert P, Dumas PY, Récher C, Lebon D, Berthon C, Michallet M, Pigneux A, Nguyen S, Chantepie S, Vey N, Raffoux E, Celli-Lebras K, Gardin C, Lambert J, Malfuson JV, Caillot D, Maury S, Ducourneau B, Turlure P, Lemasle E, Pautas C, Chevret S, Terré C, Boissel N, Socié G, Dombret H, Preudhomme C, Itzykson R. Fenwarth L, et al. Among authors: malfuson jv. Blood. 2021 Jan 28;137(4):524-532. doi: 10.1182/blood.2020005524. Blood. 2021. PMID: 32871585 Free article.
Prognostic significance of concurrent gene mutations in intensively treated patients with IDH-mutated AML: an ALFA study.
Duchmann M, Micol JB, Duployez N, Raffoux E, Thomas X, Marolleau JP, Braun T, Adès L, Chantepie S, Lemasle E, Berthon C, Malfuson JV, Pautas C, Lambert J, Boissel N, Celli-Lebras K, Caillot D, Turlure P, Vey N, Pigneux A, Recher C, Terré C, Gardin C, Itzykson R, Preudhomme C, Dombret H, de Botton S. Duchmann M, et al. Among authors: malfuson jv. Blood. 2021 May 20;137(20):2827-2837. doi: 10.1182/blood.2020010165. Blood. 2021. PMID: 33881523 Free article.
Genetic identification of patients with AML older than 60 years achieving long-term survival with intensive chemotherapy.
Itzykson R, Fournier E, Berthon C, Röllig C, Braun T, Marceau-Renaut A, Pautas C, Nibourel O, Lemasle E, Micol JB, Adès L, Lebon D, Malfuson JV, Gastaud L, Goursaud L, Raffoux E, Wattebled KJ, Rousselot P, Thomas X, Chantepie S, Cluzeau T, Serve H, Boissel N, Terré C, Celli-Lebras K, Preudhomme C, Thiede C, Dombret H, Gardin C, Duployez N. Itzykson R, et al. Among authors: malfuson jv. Blood. 2021 Aug 19;138(7):507-519. doi: 10.1182/blood.2021011103. Blood. 2021. PMID: 34410352 Free article. Clinical Trial.
71 results